secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001641172-25-013196
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Telomir Pharmaceuticals announces BIO 2025 participation and preclinical progress for Telomir-1
--------------------------------------------------------------------------------

- Telomir will participate in the BIO International Convention 2025 in Boston from June 16-19, 2025, with scheduled partnering meetings.
- The company plans to submit an IND by year-end and initiate first-in-human clinical trials in the first half of 2026.
- Preclinical data showed retinal regeneration in AMD, lifespan extension in Progeria/Werner's, reversal of Type 2 diabetes parameters, and ~50% tumor reduction in prostate cancer model.
- Telomir launched a rare disease initiative targeting Werner's, Wilson's, Progeria, and dysphonia, and introduced Telomir-Ag2 for multidrug-resistant bacteria including MRSA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225013196/0001641172-25-013196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225013196/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer